ALKYLATING AGENTS IN BRONCHOGENIC CARCINOMA

被引：345

作者：

GREEN, RA

HUMPHREY, E

CLOSE, H

PATNO, ME

机构：

来源：

AMERICAN JOURNAL OF MEDICINE | 1969年 / 46卷 / 04期

关键词：

D O I：

10.1016/0002-9343(69)90071-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A large number of patients in a group of Veterans Administration Hospitals received a variety of alkylating agents in studies in which these agents were randomized with an inert compound. Intravenous cyclophosphamide, and possibly nitrogen mustard, had a slight favorable influence upon survival for all patients. A difference between the two agents was seen: patients with squamous cell carcinoma appeared to respond best to nitrogen mustard therapy and patients with small cell undifferentiated carcinoma to cyclophosphamide therapy, in fairly striking fashion. Over-all influences upon survival, however, were not remarkable. © 1969.

引用

页码：516 / +

页数：1

共 18 条

[1] HIGH-DOSE MUSTINE THERAPY FOR BRONCHIAL CARCINOMA
GOLDMAN, KP
[J]. BRITISH MEDICAL JOURNAL, 1963, (532): : 312 - +
[2] HAAR H, 1960, CANCER CHEMOTH REP, P41
[3] HORWITZ H, 1965, AMER J ROENTGENOL RA, V93, P615
[4] Hughes F A Jr, 1966, JAMA, V196, P343
[5] HUMPHREY EW, UNPUBLISHED DATA
[6] CELL TYPE AND NATURAL HISTORY OF LUNG CANCER
HYDE, L
YEE, J
WILSON, R
PATNO, ME
[J]. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1965, 193 (01): : 52 - &
[7] Kaplan E. L., 1958, J AM STAT ASSOC, V53, P282, DOI DOI 10.1080/01621459.1958.10501452
[8] KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO
[9] 2-L
[10] KENDALL MG, 1961, ADVANCED THEORY STAT, V2

← 1 2 →